# AtoCap

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atocap

- Industry: Pharmaceuticals
- Headquarters: London, UK
- Website: www.atocap.com
- Total disclosed funding: $0.9M
- Latest round: Seed (Sep 1, 2015)
- Investors on record: 2

## About

AtoCap Ltd is a pharmaceutical company that specializes in developing innovative microencapsulation technologies to enhance drug delivery for recurrent urinary tract infections (UTIs). Their flagship product offers targeted treatment solutions.AtoCap Ltd focuses on advanced microencapsulation technologies and was founded by Eleanor Stride and Mohan Edirisinghe. The company is headquartered in London, UK, with a focus on developing solutions for chronic urinary tract infections. In September 2015, AtoCap Ltd raised GBP 607 thousand in Seed funding led by Mustard Seed Impact and University College London Business, valuing the company at GBP 1.42 million post-money. The total amount raised by the company stands at GBP 0.610 million, with the most recent deal occurring on 2015-09-01.AtoCap specializes in innovative microencapsulation technologies designed to enhance the delivery of pharmaceuticals, particularly targeting the treatment of recurrent and chronic urinary tract infections (UTIs). Their flagship product, CapFuran®, utilizes a proprietary electro-hydrodynamic processing method to encapsulate a combination of generic antibiotics into multi-layered capsules. This advanced formulation allows for both immediate and sustained release of the drug, ensuring targeted delivery to affected areas in the body, specifically within the bladder. The product is engineered to effectively combat uropathogenic bacterial species, including E. coli, through a time-release mechanism. AtoCap's solutions are primarily aimed at healthcare providers and institutions dealing with a substantial patient population, particularly among the elderly, who are significantly affected by UTIs. The company operates globally, focusing on markets with high incidences of UTIs, which includes North America, Europe, and parts of Asia.AtoCap generates revenue through direct sales of its microencapsulation products, notably CapFuran®, to healthcare providers and institutions specializing in urology and infectious diseases. The company's transaction structure is based on B2B relationships, where healthcare providers procure these products to enhance their treatment offerings for patients suffering from recurrent UTIs. Pricing plans are structured based on the volume of product ordered, allowing for tailored solutions that meet the specific needs of different healthcare facilities. As the market for targeted antibiotic therapies is robust, particularly given the rising prevalence of UTIs worldwide, AtoCap's revenue model capitalizes on the demand for effective, innovative treatment options. The company maintains a strong emphasis on building partnerships with medical institutions to ensure wide accessibility of its products.AtoCap Ltd aims to leverage its recent Seed funding of GBP 607 thousand to develop and launch new products targeting chronic urinary tract infections. The company is exploring expansion into new markets across North America and Asia by 2016, focusing on regions with high demand for urological health solutions. The funding will support R&D initiatives to enhance their product line and extend their market reach.

## Funding rounds

- Seed, Sep 1, 2015, $0.9M — University College London Business, Mustard Seed

## Investors

- University College London Business — Seed
- Mustard Seed — Seed